Key terms
About ITRM
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ITRM news
Apr 02
3:20pm ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Apr 01
6:30am ET
Analysts Offer Insights on Healthcare Companies: CalciMedica (CALC), Apollomics (APLM) and Iterum Therapeutics (ITRM)
Mar 28
7:02am ET
Iterum Therapeutics sees cash runway into 2025
Mar 28
7:02am ET
Iterum Therapeutics reports Q4 EPS (81c) vs. (52c) last year
Mar 06
11:30am ET
Analysts Are Bullish on Top Healthcare Stocks: Iterum Therapeutics (ITRM), Mainz Biomed B.V. (MYNZ)
Mar 06
8:15am ET
Iterum Therapeutics expects to resubmit oral sulopenem NDA in 1H of 2Q24
Feb 07
6:08am ET
Iterum Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
Feb 02
11:07am ET
Biotech Alert: Searches spiking for these stocks today
Feb 01
11:24am ET
Biotech Alert: Searches spiking for these stocks today
Jan 31
1:05pm ET
Buy Rating Affirmed for Iterum Therapeutics Following Superior Clinical Trial Results and Market Opportunity
Jan 30
7:13am ET
Iterum Therapeutics’ sulopenem shows positive results in urinary infections
Jan 19
7:39am ET
Iterum Therapeutics initiated with a Buy at Maxim
No recent press releases are available for ITRM
ITRM Financials
Key terms
Ad Feedback
ITRM Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ITRM Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range